UNCLASSIFIED

Lawrence Livermore National Laboratory

Institutional Biosafety Committee

IBC Meeting Minutes

Meeting Date	3.10.2026
Call to Order	1:29 PM
Adjourned	2:04 PM
Meeting Type	Hybrid: WebEx & In-Person All IBC Meetings are closed in accordance with the *LLNL IBC Policy on Public Information*.
Quorum	The IBC has eleven voting members. Six members, including at least one non-affiliated member, are required for a quorum.
Next Meeting Date	4.14.2026

Committee Member	Attendance	Late Arrival	Early Departure
Amy Rasley	No		
Bruce Mackinlay	Yes		
Bruce Wolfe	Yes		
Carolyn Hall	Yes		
Ed Saada	Yes		
Mike Malfatti	Yes		
Mimi Yung	Yes		
Monica Borucki	Yes		
Natalie Jouravel	Yes	1:31 PM	
Nick Watkins	Yes		1:59 PM
Rebecca MacIsaac	Yes	1:42 PM	

Non-Voting Attendees	
Attendee	**Attendance**
Elizabeth Zukoski	Yes
Gina Alvino	Yes
Julie Avila	Yes
Kul Garg	Yes
Michael Rodriguez	No
Rachel Brown	No
Tamara Mercante	Yes
Wes Overton	Yes

Protocol for Review	
PI Name	Pett-Ridge, Jennifer
Presenter Name	Wollard, Jessica & Pett-Ridge, Jennifer
Application Number	2020-008
Title	Nano Stable Isotope Probing (Nano SIP)
Type of Review	☐ New Application ☐ Amendment/Annual Review ☒ 3YR Renewal
Highest Risk Group Level	☒ RG1 ☐ RG2 ☐ RG3
Highest Containment Level	☒ BSL1 ☐ RG2 ☐ RG3
Applicable NIH Guidelines	III-E
Discussion & Questions	• Large removal of organisms because they were destroyed or had been moved to another project. • Soil samples are taken from areas endemic for valley fever but there is a WCD for offsite sampling, and those listed on the WCD take the valley fever training. Samples are taken with a hydraulic core so they are not generating dust. Cores are then frozen; there's no sieving or lofting. Gloves and masks are worn. • Update technical language with laymen's language by spelling out acronyms for the first usage.
IBC Vote	**Motion:** ☐ Approved ☒ Approved with Amendment: **Required Amendment** • Add standard language highlighting samples at risk for valley fever, address that training is required, PPE, etc. • A.2.2 Change to No • Spell out acronyms for the first usage Motion made by: Carolyn Hall Motion seconded by: Mimi Yung **Votes**

	• For: 7 • Against: 0 • Abstain: 0 • Recused (include names): N/A **Conflict(s) of Interest:** N/A

Protocol for Review	
PI Name	Yung, Mimi
Presenter Name	Yung, Mimi
Application Number	2017-006
Title	Bacterial Synthetic Biology
Type of Review	☐ New Application ☐ Amendment/Annual Review ☒ 3YR Renewal
Highest Risk Group Level	☐ RG1 ☒ RG2 ☐ RG3
Highest Containment Level	☒ BSL1 ☐ BSL2 ☐ BSL3
Applicable NIH Guidelines	III-D-2-a, III-E-2
Discussion & Questions	• HSD had a question regarding need to offer TB testing or immunization. Biosafety confirmed this is not necessary because the work does not involve work with Mycobacterium tuberculosis (Mtb), it only involves cloning a gene from Mtb. • The committee reviewed work involving transferring enzymes commonly used in biotechnology from RG2 and RG3 agents into RG1 organisms. These enzymes are non-hazardous and not involved in pathogenesis or virulence and were determined to not increase the risk of the modified agent(s) and work with these genetically modified organisms can safely be lowered from BSL-2 to BSL-1 containment. Under Section IV-B-2-b-(3), the IBC has the authority to lower the containment level for these experiments.
IBC Vote	**Motion:** ☒ Approved ☐ Approved with Amendment: **Required Amendment**

	• N/A Motion made by: Ed Saada Motion seconded by: Bruce Wolfe **Votes** • For: 5 • Against: 0 • Abstain: 3 • Recused (include names): 0 **Conflict(s) of Interest:** Mike Malfatti, Mimi Yung

Protocol for Review	
PI Name	Saada, Ed
Presenter Name	Saada, Ed
Application Number	2022-010
Title	CRISPR Gene Editing and High-Throughput Anti-Viral Screening
Type of Review	☐ New Application ☐ Amendment/Annual Review ☒ 3YR Renewal
Highest Risk Group Level	☐ RG1 ☒ RG2 ☐ RG3
Highest Containment Level	☐ BSL1 ☒ BSL2 ☐ BSL3
Applicable NIH Guidelines	III-D-1-a, III-D-2-a, III-D-3a, III-E
Discussion & Questions	• HSD indicated that they no longer keep the COVID vaccine in stock and inquired about requirement to keep in stock and offer to researchers working with SARS-CoV-2. The Biosafety Office reminded HSD that we are required to offer the vaccine to researchers actively working with SARS-CoV-2 but that researchers could decline the vaccine or opt to get it elsewhere. Biosafety recommended a separate meeting to discuss utility of stocking the vaccine vs. acquiring it on an as-needed basis based on need. • The newly proposed project uses a name that is not an acronym and is intended to serve solely as a unique identifier.

IBC Vote	**Motion:** ☒ Approved ☐ Approved with Amendment: **Required Amendment** • N/A Motion made by: Mike Malfatti Motion seconded by: Mimi Yung **Votes** • For: 6 • Against: 0 • Abstain: 1 • Recused (include names): 0 **Conflict(s) of Interest:** Ed Saada

Committee Business	
New Business	Acknowledgement of Service
Educational Opportunity	N/A
Review of Previous Meeting Minutes	**Motion:** ☒ Approved ☐ Approved with Amendment: **Required Amendment** • N/A Motion made by: Carolyn Hall Motion seconded by: Mike Malfatti **Votes**

	• For: 4 • Against: 0 • Abstain: 3 • Recused (include names): 0 **Conflict(s) of Interest:** N/A

This work performed under the auspices of the U.S. Department of Energy by Lawrence Livermore National Laboratory under Contract DE-AC52-07NA27344.